Inhibikase Therapeutics, Inc.
NASDAQIKT short squeeze pressure intensifies: utilization hits 100%, matching 52-week peak as 23.5% of float trades on loan.
Snapshot as of 25 Jun 2026
Inhibikase Therapeutics enters its May 15 earnings report as one of the most heavily shorted small-cap biotechs in its peer group — yet analysts are unambiguously bullish, creating a tension the quarterly print will…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for IKT — free to start on ORTEX.
Sign up for free →Open IKT on ORTEXPulses are triggered by ORTEX's live data feeds. The full signal history, thresholds, and alerts are on ORTEX.
Live IKT data →